首页 | 本学科首页   官方微博 | 高级检索  
     

用改良的竞争性聚合酶链反应测定乳腺癌癌基因HER2、mdm-2和myc的扩增
引用本文:邓国仁,何洛文,吕有勇,黄信孚,李吉友,徐光炜. 用改良的竞争性聚合酶链反应测定乳腺癌癌基因HER2、mdm-2和myc的扩增[J]. 中华医学杂志, 1995, 0(2)
作者姓名:邓国仁  何洛文  吕有勇  黄信孚  李吉友  徐光炜
作者单位:北京市肿瘤防治研究所
摘    要:使用改良的竞争性聚合酶链反应法,对15例乳腺癌基因HER2、mdm-2和myc的扩增进行测定,发现分别有5、6和6例存在扩增。其中HER2和mdm-2基因的扩增分别与肿瘤临床分期和淋巴结转移存在相关关系,说明上述基因扩增的测定可以成为对乳腺癌病人进行预后判断和研究乳腺癌生物学行为的指标。这种方法具有准确、操作简单、对DNA质量和数量要求不严格、不需使用同位素等优点。

关 键 词:乳腺肿瘤,聚合酶链反应,基因增强

Amplification of oncogenes HER2, mdm-2and myc in brest cancer determined by modified coinpet-itive PCR
Deng Guoren, He Luowen, Lu Youyong, etal. Amplification of oncogenes HER2, mdm-2and myc in brest cancer determined by modified coinpet-itive PCR[J]. Zhonghua yi xue za zhi, 1995, 0(2)
Authors:Deng Guoren   He Luowen   Lu Youyong   etal
Abstract:he amplification of oncogenes HER2 , mdm-2 andmyc was determined with a modified competitive PCR.The HER2, mdm-2 and myc genes were found to am-plify in 5 , 6 and 6 out of 15 patients with breast cancerrespectively. The amplification of HER2 and mdm-2correlated with advanced tuniors and lymphnode in-volvement respectively, indicating that the amplificationof the oncogenes is a useful indicator for the prognosis ofpatients with breast cancer and for the study of the bio-logical bahaviors of tumors. This modified non-radioac-tive competitive PCR is simple to handle (even for DNAsamples with low quantity and low quality) , and accu-rate for measuring the copy numbers of genes.
Keywords:Breast neoplasms Polymerasechain reaction Gene amplification  
本文献已被 CNKI 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号